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ABSTRACT 
Pantoprazole drug is utilized for treatment of gastric and 
duodenum ulcer, utilized as proton pump inhibitor, belongs to 
group of Benzimidazole. Pantoprazole drug undergoes through 
acidic medium of the stomach, can be coated with enteric 
coating polymer after that they will safely distribute the drug in 
the musculin intestine, for the degradation. Pantoprazole has 
been prepared by direct compression method utilizing variant 
excipient on different concentration like crosscarmellose 
sodium as disintegrating agent, dicalcium phosphate as diluents 
and mannitol. Direct compression is economic since it requires 
fewer unit operations, compare to wet granulation method. This 
direct compression method require less equipment, need low 
power consumption, less space, short duration, leading to low 
cost of tablets dosage form. The prepared tablets has been 
evaluated by different evaluation parameter like hardness, 
surface morphology, weight variation, friability, percentage 
yield, and it was found that the results comply with official 
standards. The in-vitro release has been evaluated utilizing pH 
1.2 acidic buffer and pH 6.8 phosphate buffer. The in-vitro 
release study showed that the prepared and evaluated 
pantoprazole tablets are capable to sustain release drug in the 
intestine. 
Keyword: - Pantoprazole sodium, enteric coated, ulcer,in-vitro 
release. 
INTRODUCTION 
Tablets are utilized as solid dosage forms containing 
medicinal substances or excipient with or without 
diluents. Solid dosage forms are the most widely used 
form of medication both by pharmaceutical company as 
well as medicos and patients. They provide safe and 
facile ways of active pharmaceutical ingredients (API) 
administration with great physicochemical stability in 
comparison to some other different dosage forms, and 
also gives designates of precise dosing 1. An enteric 
coating is an opportune barrier applied to oral medication 
(solid dosage form) that controls the targeted location in 
the digestive system where it is absorbed. Enteric coating 
refers to theminuscule intestine, therefore enteric 
coatings reduces release of medication before it reaches 
the minuscule intestine. Maximum enteric coatings 
perform by presenting a surface that is stable at the 
highly acidic pH found in the stomach, but rapidly 
breaks down at a low acidic mediapH2. Pantoprazole 
drugs with short half-lives are ideal dosage form for 
sustained drug distribution. Pantoprazole sodium is a 
white to off-white crystalline powder, racemic and has 
weakly basic and acidic properties. It is liberatingly 
soluble in dihydrogen monoxide, very slightly soluble in 
phosphate buffer at pH 7.4, and virtually insoluble in n-
hexane. The stability of the compound in aqueous 
solution is pH-dependent. Different drugs have been 
marketed as sustained release tablets according to their 
cost efficacy and excellent patient compliance. Now 
present study, we made an endeavor to distribute 
pantoprazole in a sustained manner utilizing enteric 
coated release tablets and studied their efficacy for 
treating ulcer3. Several types of studies are published 
regarding pantoprazole pharmacokinetics, veryless 
studies of them have fixated on the proof of 
bioequivalence between two formulations. For such 
types of drugs, enteric coating mixed to the formulation 
inclines to avoid the stomach's acidic exposure, 
distributing them instead to a fundamental pH 
environment (intestines pH 5.5) where they do not 
degrade, and give their desired therapeutic effect. 
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ABSTRACT 
Enset (Ensete Ventricosum, Family Musaceae) is a plant indigenous to Ethiopia, it is often called „false banana” for its close 
resemblance to banana plant. The plant is the most important staple food for millions of people in the south and southwestern 
parts of Ethiopia. Enset plant contains starch as its major contents. The starch has been investigated for its physico-chemical 
properties including granule size, X-ray diffraction pattern, amylose content, gelatinization behavior, stability and various 
rhelogical properties of the gel. Based on its physico-chemical properties the starch was evaluated for various pharmaceutical 
applications such as in tablet binder and disintegrant. Several modifications were also attempted on the native enset starch so as 
to improve and modulate its physiochemical properties. Hence, this review aims to summarize the knowledge on the properties 
of enset starch and its pharmaceutical applications.  
Key words: Enset Starch, Physico-Chemical Properties, Pharmaceutical Application 
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The aim of this study is to prepare and formulae of 
enteric coated pantoprazole tablet. Proton pump 
inhibitors (PPIs) reduced gastric acid secretion by 
concrete inhibition of the H+/K+- ATPase in the gastric 
parietal cell. This process follows with absorption of the 
Proton pump inhibitors in the parietal cell. Proton pump 
inhibitors are related to bases, so protonation takes place 
in the acidic region of the secretory canaliculus of the 
parietal cell. The main aim of an oral tablet is to provide 
a certain and agreeable amount of drug to the human 
body through GI system. Studies on bioavailability of 
drugs from a given study showed that in many situations 
tablets with same drug and drug amount did not give the 
same therapeutic effect. Formulation excipient in the 
tablet, physical which is responsible for variation in the 
quantified dissolution profile and therapeutic 
replication4.Drugs such as pantoprazole which have an 
irritant effect on the stomach and must be absorbed in the 
gastrointestinal tract and because it is unstable under 
acidic conditions, enteric coated distribution systems are 
required. Similarly, certain groups of Azoles are acid-
unstable. For such types of drugs, enteric coating 
integrated to the formulation inclines to eschew the 
stomach's acidic exposure, distributing them instead to a 
fundamental pH environment (intestines pH 5.5 and 
above)where they do not degrade, and give their desired 
action2.The different release characteristics of the enteric 
polymers have profound impact upon the 
pharmacokinetic parameters of the drug 5, 6. An Ideal 
enteric polymer should possess a hydrophilic and 
hydrophobic monomeric unit. Methacrylic acid and 
methyl methacrylate could make an ideal hydrophilic and 
hydrophobic unit respectively. Such compositions of 
polymer are essentially insoluble in gastric fluids and 
may avail conveyance of drugs across the proximal 
alimentary tract without degradation 7. Pantoprazole is 
highly selective to acid secretive gastric parietal cells and 
its action is irrespective of the type of stimuli. Despite its 
several therapeutic benefits including maximal efficacy-
safety ratio 8. 
Ideal properties of enteric coating material
9, 10, 11. 
 Resistance to gastric fluids  
 Susceptible/permeable to intestinal fluid  
 Compatibility with most coating solution 
components and the drug substrate  
 Formation of continuous film  
 Nontoxic, cheap and ease of application  
 Ability to be readily printed 
Advantage of enteric coated tablet
12
 
1. Enteric coating is employed for a number of 
therapeutic, safety, and medical reasons. Some drugs 
are procure when directly exposed to the mucosa, 
gastric, including aspirin and vigorous electrolytes 
such as NH4Cl. 
2. Enteric coating is one method of reducing or 
eliminating vexation from such drugs. There are 
other drug that if abandonment in the stomach may 
create nausea and vomiting. 
3. The low pH of the stomach destroy other drug, and 
hence enteric coating may be the desire to abandon 
the drug undiluted and in the highest concentration 
possible within the intestine. 
4. In case of repeat action and other controlled release 
dosage form, the influence of altering the profile of 
the drug on total drug bioavailability, distribution, 
and pharmacokinetics must be investigated. 
Disadvantages of tablet coating  
1. Limitations of sugar coating such as relatively high 
cost, long coating time and high bulk had led to the 
use of other coating materials.  
2. However the process of coating is tedious and time-
consuming and it requires the expertise of highly 
skilled technician. 
Coating equipment 
A modern tablet coating system combines several 
component – 
 A coating pan 
 A spraying system 
 An air handling unit 
 A dust collector 
 
Different types of polymer used in enteric coating tablets
13– 
Polymers 
 
Dissolution pH 
Shellac (esters of aleurtic acid)  
 
7.0 
Cellulose acetate phthalate (CAP)  
 
6.2 
Poly(methacrylic acid-co-methyl methacrylate)  
 
5.5-7.0 
Cellulose acetate trimellitate (CAT)  
 
5.0 
Poly(vinyl acetate phthalate) (PVAP)  
 
5.0 
Hydroxypropyl methylcellulose phthalate (HPMCP)  
 
4.5-5.5 
 
New materials used for tablet coating  
 Zein 
 Aqua-Zein, which is an aqueous zein formulation containing no alcohol.  
 Amylose starch and starch derivatives  
 Dextrin. 
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Patents:- 
Patent No. Title Result 
 20090214602 Oral Dosage Forms Including An 
Antiplatelet Agent And An 
Enterically Coated Acid Inhibitor 
Provides oral dosage forms comprising an antiplatelet agent and an 
enterically coated acid inhibitor 
14
. 
7217429 Tableted oral a compound of 
benzimidazole labile in an 
pharmaceutical dosage form, with 
enteric coating, containing acid 
medium 
The pharmaceutical dosage form consists of a plurality of units 
containing a benzimidazole compound labile in an acid medium as the 
active principle, each unit being comprised of an inert core, a layer 
containing the active principle and an intermediate layer. These units, 
commixed with compression excipients, compressed and coated with 
an enteric coating, provide a tableted pharmaceutical dosage form 
opportune for oral administration for averting and treating disorders 
cognate to eccentric secretion of gastric acid 
15
. 
20070269509 Enteric Coated Pharmaceutical 
Oral Formulations Comprising 
Acid-Labile Active Substances, 
and a Method Thereof 
This invention relates to an oral pharmaceutical formulation 
composed by a direct coating of an enteric layer containing 
polyethylene glycol as a plasticizer on a core containing an acid-labile 
pantoprazole 
16
. 
 20070042033 Pantoprazole multiparticulate 
formulations 
Pantoprazole sodium multiparticulates are described which eschew 
sticking to nasogastric and gastronomy tubes 
17
. 
20080003281  Modified Release Tablet 
Formulations for Proton Pump 
Inhibitors 
An oral solid pharmaceutical dosage form comprising an acid 
sensitive proton pump inhibitor (PPI) as single active drug, 
relinquishing the PPI in two separate pulses, one immediate and one 
delayed
18
. 
 20050042277  Pharmaceutical compositions 
having a swellable coating 
A pharmaceutical dosage form containing a pharmaceutical active 
that is not stable in the presence of acid comprises a core containing 
the active and a disintegrant, a swellable coating circumventing the 
core, and an enteric coating circumventing the swellable coating 
19
. 
7431942 Orally disintegrable tablets 
 
An orally disintegrable tablet of the present invention, which 
comprises  fine granules having an average particle diameter of 400 
μm or less, which fine granules comprise a composition coatedby an 
enteric coating layer 
20
. 
 20090280175  Multilayer Proton Pump Inhibitor 
Tablets 
Multilayer tablets of a proton pump inhibitor essentially bioequivalent 
in terms of plasma Cmax and AUC to capsules and/or tablets 
consisting of multiple unit pellets of the protonpump inhibitor are 
provided 
21
. 
20120064159 Multilayer Oral Tablets 
Containing a Non-Steroidal Anti-
Inflammatory Drug and/or 
Acetaminophen 
Multilayer tablets of a non-steroidal anti-inflammatory drug (NSAID) 
and/or acetaminophen for oral administration containing an 
immediate release layer or layers containing a NSAID and/or 
acetaminophen and/or a second therapeutic agent and an elongated 
release layer containing a NSAID and/or acetaminophen are provided 
22
. 
 8574625 Tablet dosage form 
 
 
The present invention relates to novel tablet dosage forms and 
methods of preparing these forms, which can be used for different 
classes of pharmaceutical active ingredients posing stability issues in 
a single unit system
23
. 
 20090220621 Pharmaceutical compositions of a 
non-enteric coated proton pump 
inhibitor with a carbonate salt and 
bicarbonate salt combination 
A method for treating gastric acid disorders with a non-enteric coated 
proton pump inhibitor in a pharmaceutically 
acceptable carrier including a bicarbonate salt of a Group IA metal 
and a carbonate salt of a Group IA metal; and a pharmaceutical 
composition of a non-enteric coated proton pump inhibitor in a 
pharmaceutically acceptable carrier including a bicarbonate salt of a 
Group IA metal and a carbonate salt of a Group IA metal are 
disclosed
24
. 
7785650 Method for dip coating dosage 
forms 
 
Water soluble, gelatin-free dip coatings for pharmaceutical solid 
dosage forms such as tablets comprising HPMC and xanthan gum, 
carrageenan, and mixtures thereof, or HPMC and castor oil or 
maltodextrin
25
. 
6953808 Method for treating gastric 
disorders using optically pure (−) 
pantoprazole 
 
Methods and compositions are disclosed utilizing optically pure (−) 
pantoprazole for the treatment of ulcers in humans while substantially 
reducing the concomitant liability of adverse effects associated with 
the racemic mixture of pantoprazole 
26
. 
7387792 Pharmaceutical composition for 
compressed annular tablet with 
molded triturate tablet for both 
intraoral and oral administration 
New pharmaceutical compositions in unit dosage form are disclosed 
for both intraoral and oral administration to a patient
27
. 
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MECHANISM OF ENTERIC COATED TIME-
RELEASE PRESS COATED (ETP) TABLETS- 
ETP tablets are consist of three layers, first drug 
containing core tablet (rapid release function), the press 
coated swellable hydrophobic polymer layer (Hydroxy 
propyl cellulose layer (HPC), time release function) and 
an enteric coating layer (acid resistance function).The 
tablet does not relinquish the drug in the stomach due to 
the acid resistance of the outer enteric coating layer. The 
enteric coating layer rapidly dissolves after gastric 
vacating and the intestinal fluid commences to gradually 
wear away the press coated polymer (HPC) layer. 
Efficient drug release occurs when the erosion front 
reaches the core tablet since the erosion process takes a 
long time as there is no drug release period (lag phase) 
after gastric emptying. The duration of lag phase (drug 
release period) is controlled either by the weight or 
composition of the polymer (HPC) layer 28, 29. 
METHODS: 
For developing and evaluating a pharmaceutical dosage 
form, it is very much paramount to quantify the physico-
chemical properties of the drug molecule & the other 
derived properties of the drug powder. This first phase of 
the studies is known as pre-formulation studies which 
provide variants of information about the formulation 
development. 
Preparation of sustained release tablet of 
pantoprazole by wet granulation method -
Pantoprazole tablets has been prepared by the wet 
granulation method. Required quantity of pantoprazole, 
and variants of polymer hydroxypropylmethylcellulose, 
cassava starch and polyvinyl pyrrolidone and Avicel PH 
102 are weighed according to the formula and transferred 
into a mortar with pestle and integrated exhaustively. 
The powder mass is commixed with a 5 % starch paste to 
found a sluggy mass, which is passed by a sieve with 
opening pore of 1.4 mm to found granules. The prepared 
granules are dried at 40 °C for 4 h. The dried granules 
are screened by sieves of 0.71 mm and 0.355 mm and 
stored for further studies. Designated quantities of 
magnesium stearate and talc are determinately integrated 
and commixed exhaustively. The mixture is directly 
punched into tablets weighing about 200 mg (containing 
40 mg of pantoprazole), by utilizing a rotary tablet 
compression machine, and 8-mm diameter Concave 
punches. The different batches of pantoprazole tablets 
has been accumulated and stored in airtight containers 30. 
Preparation of enteric coated tablet by spray 
coatingtechnique
31 
Preparation of core tablets-Granules has been prepared 
using wet granulation method. Drug and other excipients 
were passed through # 80 and add sufficient quantity of 
binding agent slowly to get dough mass. The mass is 
sieved through # 8 and dried at 45ºC for about 1 hrs. and 
then these granules are passed through # 20 and 
lubricated with magnesium stearate. Mixed blend is 
compressed into tablets on single punch tablet 
compression machine to a weight of 250 mg each with 
thickness of 4.46 ± 0.21 mm and diameter of 7.9 mm 
using shallow concave plain/plain punch. 
Preparation of enteric coating solution-Weighed amount 
of pectin is dissolved in 50 ml of water and ethyl 
cellulose is dissolved in 50 ml of isopropyl alcohol. The 
two solutions are then mixed well to form a 
homogeneous solution and PEG-6000 was added as a 
plasticizer.  
Coating of core tablets-Enteric coating of the compressed 
tablets is achieved by standard coating pan technique. 
Tablets are taken and are coated in a pan coater at 50 
rpm at a temperature of 50ºC and at a flow rate of 10 
ml/min. Coating is carried out with spraying method and 
dried. These solutions are applied over tablets using 
spray gun at appropriate pressure. The coated tablets are 
primarily dried using heat blower and secondarily dried 
in tray drier. 
Coating methodology- The coating is executed in a 12 
inch conventional coating pan, charged with 1 kg of core 
tablets. The tablet bed is pre-warmed to 40 ºC. Coating 
solution is applied through utilizing external spray gun 
with low pressure air atomized liquid spray system. The 
temperature of the system is maintained at 55 ºC utilizing 
external drying system, throughout the coating process. 
The pan speed is maintained at 12 rpm. The seal coating 
solution is first applied to build up a 2% weight gain of 
the tablets. Upon completion of the seal coating, the 
tablets are approvalto rotate in the pan at a more gradual 
rate, after that drying of the tablets. The seal coat is 
followed by Acryl-EZE coating. The coating material 
deposit has beenmeasured to obtain different weight 
gains such as 8%, 10% and 16% from its weight. The 
tablets are checked for the weight gain before and after 
the application of designated time of coating in order to 
verify the procurement of desired 32. 
Coating of compressed pantoprazole sodium tablets
 
The enteric coating solution has been prepared by simple 
solution method utilizing 6 % w/w and 8% W /W of 
Eudragit L100 (E1 and E2) or cellulose acetate phthalate 
(C1 and C2) as an enteric polymer. The PEG is utilized 
as plasticizer and acetone and isopropyl acetone is 
utilized as solvent. This mixture is perpetually stirred for 
1h with paddle mechanical stirrer and the stirred coating 
solution is again filtered through muslin cloth to obtain 
coating solution. 
Enteric Coating of Pantoprazole Sodium 
Sesquihydrate Compressed Tablets by Dipping 
Method
 
The compressed tablets have been coated with enteric 
coating polymer (Eudragit L100 or cellulose acetate 
phthalate or Drug coat L100) solution by dipping 
method. Desired coating tablet is performed for the 
dipping and weight gain is achieved. The coated tablets 
are studied for its weight variation, thickness, uniformity 
of drug content and in vitro dissolution study 33. 
Analytical method
 
This method involves the identification of the active 
pharmaceutical ingredient, evaluation of pharmacopoeial 
compliance and development of analytical procedure 
34
.
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EVALUATION OF THE TABLET:
 
Hardness test:
 
The hardness is carried for 5 tablets utilizing Monsanto 
hardness tester.The average hardness of the tablets are 
obtained35.  
Weight variation test: 
Tablets has been discarded arbitrarily and weighed 
individually. The average weight has been calculated and 
individual weight compared to the average weight. The 
tablet passes the test if not more than two of the 
individual weights deviate from the average weight by 
more than ± 7.5% and none deviated by twice ± 7.5% 35. 
Size Analysis by Optical Microscopy
 
Dry granules are uniformly spread on a glass slide. 
Granule particle size are quantified along the longest and 
the shortest axes (cross shaped quantification) utilizing 
an optical microscope after calibration. Average of these 
two readings is given as the mean diameter of particles. 
The diameter of at least 50 granules in each batch has 
been determined 36. 
Disintegration time 
 
The disintegration time of the coated tablets is 
determined by utilizing the USP model disintegration 
apparatus. Six tablets are placed in the basket rack 
assembly, and is run for 2 hours in 0.1 N Hcl media with 
the discs. The tablets are abstracted from the solution, 
gently dried by bloating. The test is then continued by 
placing the tablets in phosphate buffer pH 6.8, for 1 h, 
maintaining the temperature at 37±2 oC37, 38. 
Stability studies 
A study is carried out to assess the stability of the 
pantoprazole sodium sesquihydrate cellulose acetate 
phthalate coated tablet formulation. Generally, the 
observation of the rate at which the product degrades 
under mundane room temperature requires a long time. 
To achieve, this undesirable delay, the principles of 
expedited stability studies are adopted. The tablets are 
packed in glass container. Stability studies are carried out 
at 40°C and 75% RH over a period of 1 month. Samples 
are evaluated at 10th, 20th and 30th days for different 
parameters such as physical appearance, hardness, 
weight variation, drug content and dissolution39. 
Angle of repose 
The frictional forces in a loose powder can be quantified 
by the angle of repose. This is the maximum angle 
possible between the surface of a pile of powder and the 
horizontal plane. Sufficient quantities of pantoprazole it 
composed a heap, which physically contacted the tip of 
the funnel. The height and radius of the heap are 
quantified. The angle of repose is calculated utilizing the 
formula 40, 41. 
Angle of repose (θ) = tan-1 (h/r) 
Where, h – Height of the pile in cm 
r – Radius of the pile 
 
 
Bulk density 
Accurately weighed granules are conscientiously 
transferred in to graduated quantifying cylinder. The 
granules bed is then made uniform and the volume 
occupied by the granules is noted as per the graduation 
marks on the cylinder as mL. It is expressed in gm/mL 
and is calculated utilizing the following formula42. 
Dissolution Test 
The dissolution test is conducted utilizing simulated 
gastric fluid (0.1N HCl) and intestinal fluid (phosphate 
buffer, pH-6.8) as dissolution medium. Utilizing 
simulated gastric fluid, 900 ml of 0.1N HCl is placed in 
the vessel and sanctioned to come to 37 ± 0.5°C. Then, 
pantoprazole tablets are placed in six baskets, one in 
each basket and stirrer is rotated at 100 rpm for 2 hrs. 
After 2 hrs. The medium is thrown to observe the 
integrity of coating layer of tablets. The coating layer is 
found to remain intact. Immediately, same tablets are 
placed in phosphate buffer (pH-6.8) at same rotation 
speed and temperature as mentioned above for 1 hr. 
After 15, 30 and 45 min, sample of 5 ml is pipetted out 
and same volume of fresh phosphate buffer is integrated 
to keep volume of the dissolution medium constant. The 
sample is diluted to 15 ml and the absorbance 
isquantified and calculation is done utilizing Lambert 
beer‟s law. Similarly, the absorbance of known 
concentration of standard solution of pantoprazole is 
quantified and percent drug release has been calculated 
43.
 
Release kinetics. 
The in vitro release data obtained from CAP coated 
tablets, Eudragit L100 coated tablets and drug coat L100 
coated tablets are fitted to various kinetic models such as 
zero-order, first-order, Higuchi and Korsmeyer-Peppas 
models. The abandonment of pantoprazole from the 
tablets is first-order diffusion controlled, as designated 
by highest R2 values 44. 
Accelerated stability studies 
Stability of a drug in a dosage form at different 
environmental conditions is consequential as it 
determines the expiry date of that particular formulation. 
Transmutations in the physical appearance, color, odor, 
taste or texture of the formulation denote the drug 
instability. The stability studies are carried out at 40 ± 2 
°C with 75 ± 5%% RH WH. There are no consequential 
variation in their physical appearance, average weight of 
tablets and hardness. It is observed that the initial drug 
content and the drug contents of the samples analyzed 
after 1, 2, 3 month of storage are closed. The 
abandonment profile additionally not showed any 
paramount changes denoting that there are no 
consequential changes in the physical as well as 
chemical characteristics of the formulation. Hence, it can 
be concluded from the results that the developed tablets 
are stable and retain their pharmaceutical properties over 
a period of 3 month 45. 
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Drugs Polymer Interaction Study by FTIR 
spectrophotometer: 
FT-IR spectroscopy study is carried out discretely to 
ascertain, the compatibility between the drug 
pantoprazole and the different polymer hydroxypropyl 
methylcellulose, Cassava starch, polyvinyl pyrrolidone 
utilized for the preparation of tablets. The FT-IR is 
performed for drug, polymer and the physical mixture of 
drug polymer 46. 
Friability test 
The friability is tenacious utilizing Roche friabilator and 
expressed in percentage. 20 tablets from each batch are 
weighed discretely (Winitial) and placed in the 
friabilator, which is then operated for 100 revolutions at 
25 rpm. The tablets were reweighed (Wfinal) and the 
percentage friability (F) is calculated for each batch by 
utilizing the formula 47. 
In-Vitro Release Studies 
The in vitro dissolution studies 8 for all the formulations 
are carried out in two steeps, utilizing USP apparatus 
type II at 100 rpm. The dissolution medium consisted of 
Hydrochloric acid buffer solution pH - 1.2 (900 ml), and 
Phosphate buffer, maintained at 37 0C ± 0.5 0C. The 
drug release at different time intervals is quantified by 
UV-visible spectrophotometer (Phosphate buffer pH – 
6.8). The abandonment studies are conducted in triplicate 
48. 
Physicochemical evaluations of coating films 
The same polymer solution is adjusted to prepare the 
polymeric films and is subjected for the thickness of the 
dried films is tenacious by digital micrometer. The film 
solubility is studied with phosphate buffer (pH 1.2 and 
6.8). The 1×1 cm2 coating film is discarded, weighed 
and transferred in a beaker containing 20 mL of 
designated phosphate buffer (pH 1.2 and 6.8) medium, 
which is in a magnetic stirrer for 1 h at 37 °C and 
determinately film solubility is examined 
49
.
 
CONCLUSION 
Ulcers are crater-like sores which form in the lining of 
the stomach, just below the stomach at the 
commencement of the minuscule intestine in the 
duodenum. An ulcer is the result of an imbalance 
between truculent and defensive factors. Pantoprazole is 
a superseded benzimidazole derivative that targets 
gastric acid proton pumps, the final ordinary pathway for 
gastric acid secretion. The drug covalently binding to the 
proton pumps, causing perpetuated inhibition of gastric 
acid secretion. The stability of pantoprazole is a function 
of pH and it rapidly degrades in acid medium of the 
stomach, but has acceptable stability in alkaline 
conditions. Therefore, pantoprazole should be distributed 
into the intestine. Hence, an endeavor is made to 
formulate a sustained release drug distribution system for 
pantoprazole by utilizing sundry enteric coating 
polymers. Various percentage of the excipient are withal 
used to get best formulations with high bioavailability. 
Evaluation experiments such as friability, hardness, 
content uniformity, thickness, weight variation, 
disintegration time are carried out and found that the 
results are complete satisfactory.  
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